User login
In the article, “When can infants and children benefit from probiotics?” (J Fam Pract. 2016;65:789-794), Dassow et al recommended probiotics as a therapeutic tool for reducing abdominal pain associated with pediatric irritable bowel syndrome (IBS). There are several types of functional disorders in childhood with related abdominal pain, the most common of which are IBS and functional abdominal pain (FAP).1,2
Several recent randomized placebo-controlled trials—one of which I led—have shown that Lactobacillus reuteri DSM 17938 is a beneficial treatment for FAP in children.3-5 When compared with placebo, this probiotic agent significantly reduced the frequency and intensity of FAP in children.
Family physicians should consider this probiotic microorganism as a potential therapeutic tool for IBS, as well as childhood FAP.
Zvi Weizman, MD
Beer-Sheva, Israel
1. Childhood functional GI disorders: child/adolescent. In: Drossman DA CE, Delvaux M, Spiller RC, et al, eds. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006:895-897.
2. Brown LK, Beattie RM, Tighe MP. Practical management of functional abdominal pain in children. Arch Dis Child. 2016;101:677-683.
3. Romano C, Ferrau’ V, Cavataio F, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014;50:E68-E71.
4. Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: A randomized, double-blind, placebo-controlled trial. J Pediatr. 2016;174:160-164.e1.
5. Jadrešin O, Hojsak I, Mišak Z, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children - RCT study. J Pediatr Gastroenterol Nutr. 2017;64:925-929.
In the article, “When can infants and children benefit from probiotics?” (J Fam Pract. 2016;65:789-794), Dassow et al recommended probiotics as a therapeutic tool for reducing abdominal pain associated with pediatric irritable bowel syndrome (IBS). There are several types of functional disorders in childhood with related abdominal pain, the most common of which are IBS and functional abdominal pain (FAP).1,2
Several recent randomized placebo-controlled trials—one of which I led—have shown that Lactobacillus reuteri DSM 17938 is a beneficial treatment for FAP in children.3-5 When compared with placebo, this probiotic agent significantly reduced the frequency and intensity of FAP in children.
Family physicians should consider this probiotic microorganism as a potential therapeutic tool for IBS, as well as childhood FAP.
Zvi Weizman, MD
Beer-Sheva, Israel
In the article, “When can infants and children benefit from probiotics?” (J Fam Pract. 2016;65:789-794), Dassow et al recommended probiotics as a therapeutic tool for reducing abdominal pain associated with pediatric irritable bowel syndrome (IBS). There are several types of functional disorders in childhood with related abdominal pain, the most common of which are IBS and functional abdominal pain (FAP).1,2
Several recent randomized placebo-controlled trials—one of which I led—have shown that Lactobacillus reuteri DSM 17938 is a beneficial treatment for FAP in children.3-5 When compared with placebo, this probiotic agent significantly reduced the frequency and intensity of FAP in children.
Family physicians should consider this probiotic microorganism as a potential therapeutic tool for IBS, as well as childhood FAP.
Zvi Weizman, MD
Beer-Sheva, Israel
1. Childhood functional GI disorders: child/adolescent. In: Drossman DA CE, Delvaux M, Spiller RC, et al, eds. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006:895-897.
2. Brown LK, Beattie RM, Tighe MP. Practical management of functional abdominal pain in children. Arch Dis Child. 2016;101:677-683.
3. Romano C, Ferrau’ V, Cavataio F, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014;50:E68-E71.
4. Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: A randomized, double-blind, placebo-controlled trial. J Pediatr. 2016;174:160-164.e1.
5. Jadrešin O, Hojsak I, Mišak Z, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children - RCT study. J Pediatr Gastroenterol Nutr. 2017;64:925-929.
1. Childhood functional GI disorders: child/adolescent. In: Drossman DA CE, Delvaux M, Spiller RC, et al, eds. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006:895-897.
2. Brown LK, Beattie RM, Tighe MP. Practical management of functional abdominal pain in children. Arch Dis Child. 2016;101:677-683.
3. Romano C, Ferrau’ V, Cavataio F, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014;50:E68-E71.
4. Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: A randomized, double-blind, placebo-controlled trial. J Pediatr. 2016;174:160-164.e1.
5. Jadrešin O, Hojsak I, Mišak Z, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children - RCT study. J Pediatr Gastroenterol Nutr. 2017;64:925-929.